Please assess the completion status of the following clinical trial:

Trial Title: Administration of Virus-Specific Cytotoxic T-Lymphocytes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of allogeneic (i.e. HLA matched or mismatched related or unrelated) donor stem cell transplants at risk for Adenoviral disease~* No evidence of GVHD \> Grade II at time of enrollment~* Life expectancy \> 30 days~* No severe intercurrent infections~* Lansky/Karnofsky scores \>60~* Absence of severe renal disease (Creatinine \> x 3 normal for age)~* Absence of severe hepatic disease (direct bilirubin \> 3 mg/dl or SGOT \> 500)~* Patient must be at least 30 days post transplant to be eligible to receive CTL~* Not receiving Cidofovir~* Patient has not received other viral specific CTL prophylactically within 4 weeks of receiving Adv-CTL~* Patient/guardian able to give informed consent~Exclusion Criteria:~* Patients with GVHD Grades III-IV~* Patients with hepatic or renal disease as specific above~* Patient has received other viral specific CTL (e.g. EBV-specific CTL or CMV-specific CTL) within 4 weeks of receiving Adv-CTL~* Patients with Adenoviral disease prior to day +30 post transplant Adenoviral diseases defined as the presence of more than two sites positive for adenovirus by culture~* Patients with less than 50% donor chimerism in either peripheral blood or bone marrow or patients with relapse of original disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virus Specific Cytoxic T lymphocytes (Type: EXPERIMENTAL): Virus Specific Cytoxic T lymphocytes

Based on this trial design, predict the completion outcome and termination type (if applicable).